Volume 7.14 | Apr 22

Prostate Cell News 7.14 April 22, 2016
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
 
TOP STORY
s-SHIP Expression Identifies a Subset of Murine Basal Prostate Cells as Neonatal Stem Cells
Researchers used a transgenic mouse model expressing GFP from the stem cell-specific s-SHIP promoter to mark putative stem cells during postnatal prostate development. They showed that cells identified by GFP expression are present transiently during early prostate development and localize to the basal cell layer of the epithelium. [Oncotarget] Full Article
ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays FREE Sample Request
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

CACUL1 Functions as a Negative Regulator of Androgen Receptor in Prostate Cancer Cells
Scientists report that CDK2-associated cullin 1 (CACUL1) directly associates with androgen receptor (AR) and suppresses AR transcriptional activity. In addition, CACUL1 represses histone demethylase LSD1-mediated AR transactivation by competing with LSD1 for AR binding. [Cancer Lett] Abstract

Long Non-Coding RNAs Harboring miRNA Seed Regions Are Enriched in Prostate Cancer Exosomes
Investigators characterized the expression of long non-coding RNAs (lncRNAs) in several prostate cancer exosomes and their parental cell lines. They showed that certain lncRNAs are enriched in cancer exosomes with the overall expression signatures varying across cell lines. [Sci Rep] Full Article

Toward the Optimization of Bombesin-Based Radiotracers for Tumor Targeting
The effect of residue and backbone modification on several parameters such as the internalization of radiolabeled peptides into PC3 and AR42J tumor cells, their affinity toward the human gastrin-releasing peptide receptor (GRPr), metabolic stability in blood plasma, and biodistribution in mice bearing GRPr-expressing PC3 xenografts was studied. [J Med Chem] Abstract

Basal Progenitors Contribute to Repair of the Prostate Epithelium Following Induced Luminal Anoikis
Researchers showed that anoikis of luminal cells in the prostate epithelium is followed by a program of tissue repair that is mediated in part by differentiation of basal epithelial cells to luminal cells. [Stem Cell Reports] Full Article | Graphical Abstract

Regulation of E3 Ubiquitin Ligase-1 (WWP1) by MicroRNA-452 Inhibits Cancer Cell Migration and Invasion in Prostate Cancer
Expression of microRNA-452 (miR-452) was significantly downregulated in prostate cancer (PCa) tissues. Transfection with mature miR-452 inhibited the migration and invasion of PCa cells. [Br J Cancer] Abstract

Computational Reconstruction of NFκB Pathway Interaction Mechanisms during Prostate Cancer
The authors provide the first steps toward computational reconstruction of interaction mechanisms of the nuclear-factor-kappa-B (NFκB) pathway in prostate cancer. They identified novel roles for ATF3, CXCL2, DUSP5, JUNB, NEDD9, SELE, TRIB1, and ZFP36 in this pathway, in addition to new mechanistic interactions between these genes and ten known NFκB pathway members. [Plos Comput Biol] Full Article

Amplification of the 9p13.3 Chromosomal Region in Prostate Cancer
The authors investigated the 9p13.3 amplification in more detail to identify genes that are potentially advantageous for cancer cells. They narrowed down the minimally amplified area and assessed the frequency of the 9p13.3 amplification. [Genes Chromosomes Cancer] Abstract

An Original Patient-Derived Xenograft of Prostate Cancer with Cyst Formation
Scientists established a unique patient-derived xenograft model to identify biomarkers for treatment efficacy and resistance and better understand prostate cancer biology. [Prostate] Abstract

Equol Inhibits Prostate Cancer Growth via Degradation of the Androgen Receptor by Skp2
Among soy isoflavones, equol suppressed androgen receptor as well as prostate-specific antigen expression most potently in androgen-dependent LNCaP cells. However, the inhibitory effect on androgen receptor expression and activity was less prominent in castration-resistant CxR and 22Rv1 cells. [Cancer Sci] Abstract

CLINICAL RESEARCH

Radioligand Therapy with 177Lu-PSMA-617 as a Novel Therapeutic Option in Patients with Metastatic Castration Resistant Prostate Cancer
The authors evaluated tumor response, adverse effects, and survival in patients undergoing radioligand therapy with 177Lu-prostate-specific membrane antigen (PSMA)-617. [Clin Nucl Med] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
 
REVIEWS
The Role of Glycans in the Development and Progression of Prostate Cancer
In the past three years, powerful tools such as glycosylation-specific antibodies and glycosylation gene signatures have been developed, which enable detailed analyses of changes in glycosylation. Thus, emerging data on these often overlooked modifications have the potential to improve risk stratification and therapeutic strategies in patients with prostate cancer. [Nat Rev Urol] Abstract

The Cross-Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications
Aberrant activation of the Wnt/β-catenin pathway and polo-like kinase 1 (Plk1) overexpression represent two common events in prostate cancer with relevant functional implications. The authors analyze their potential therapeutic significance in prostate cancer based on their role as androgen receptor signaling regulators and the pivotal role of the tumor suppressor protein phosphatase 2A modulating these pathways. [Mol Cell Biol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
SCIENCE NEWS
DelMar Pharmaceuticals Announces New Data Supporting the Unique Anti-Cancer Mechanism of VAL-083
DelMar Pharmaceuticals, Inc. announced that its collaborators from the University of British Columbia’s Vancouver Prostate Center presented results of new research related to the anti-cancer mechanism of its lead anti-cancer product candidate, VAL-083. [Press release from DelMar Pharmaceuticals, Inc. discussing research presented at the 2016 American Association of Cancer Research (AACR) Annual Meeting, New Orleans] Press Release

Merrimack Unveils Its Latest Antibody Directed Nanotherapeutic, MM-310
Merrimack Pharmaceuticals, Inc. announced positive data from preclinical studies evaluating MM-310, an antibody directed nanotherapeutic that encapsulates a newly engineered form of the highly potent chemotherapy docetaxel as a prodrug in an ephrin receptor A2-targeted liposome. [Press release from Merrimack Pharmaceuticals, Inc. discussing research presented at the 2016 American Association of Cancer Research (AACR) Annual Meeting, New Orleans] Press Release

VolitionRx Announces Study Results Showing NuQ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test
VolitionRx Limited announced that a single NuQ® biomarker assay detected 71% of early stage I prostate cancer cases at 93% specificity. [Press release from VolitionRx Limited discussing research presented at the 2016 American Association of Cancer Research (AACR) Annual Meeting, New Orleans] Press Release

From our sponsor:
Webinar: Brent Reynolds on the identification and characterization of neural stem cells.
Watch now.
 
INDUSTRY NEWS
AbbVie, University of Chicago Collaborate to Advance Cancer Research
The University of Chicago and AbbVie have entered into a five-year collaboration agreement designed to improve the pace of discovery and advance medical research in oncology at both organizations. [The University of Chicago] Press Release

University of Pennsylvania to Join First-of-Its-Kind Research Collaboration to Fight Cancer with New Immunotherapies
The University of Pennsylvania has joined an unprecedented cancer research effort, the Parker Institute for Cancer Immunotherapy, which unites six of the nation’s top medical schools and cancer centers around a shared aim of accelerating breakthrough immunotherapy research that will turn more cancers into a curable disease. The venture is backed by a $250 million gift from the Parker Foundation, making it the largest single contribution ever made to the field of immunotherapy. [University of Pennsylvania] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Summit for Cancer Immunotherapy
June 26-29, 2016
Halifax, Canada

NEW Worldwide Innovative Networking in Personalized Cancer Medicine (WIN) 2016
June 27-28, 2016
Paris, France

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Research Technologist – Mammary and Prostate Stem Cell Biology (STEMCELL Technologies Inc.)

NEW Postdoctoral Research Fellow – Molecular Epidemiology of Cancer (Fred Hutchinson Cancer Research Center)

NEW PhD Studentship – Cancer Metabolism (German Cancer Research Center)

NEW Postdoctoral Fellow – Genetic Determinants of Cancer (Memorial Sloan-Kettering Cancer Center)

Postdoctoral Fellow – Prostate Cancer (Cleveland Clinic)

Postdoctoral Fellow – Prostate Epithelial Homeostasis and Carcinogenesis (Baylor College of Medicine)

PhD Studentship – Vesicles to Target Prostate Cancer Metastasis (University of East Anglia)

Lead Scientist – Prostate Cancer (Memorial Sloan Kettering Cancer Center)

Postdoctoral Fellowship – Castration Resistant Prostate Cancer (University of Florida)

PhD Studentship – Wnt Signaling in Stem Cells and Cancer (German Cancer Research Center)

Postdoctoral Fellowship – Prostate and Breast Cancer Molecular Mechanisms (Feinberg School of Medicine)

Tenure Track Faculty Positions – Various Methods in Cancer Biology (Paul L. Foster School of Medicine)

Research Group Leader – Stress Regulated Processes During Oncogenesis (INSERM)

Postdoctoral Research Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)


Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us